0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinicopathologic Reports, Case Reports, and Small Case Series |

Viscocanalostomy for Refractory Glaucoma Secondary to Intravitreal Triamcinolone Acetonide Injection FREE

Radhika Krishnan, MA,(Cantab) MRCOphth; Nishant Kumar, MRCOphth; Peter K. Wishart, FRCOphth
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2007;125(9):1284-1286. doi:10.1001/archopht.125.9.1284.
Text Size: A A A
Published online

Intravitreal injection of triamcinolone acetonide (IVTA) has gained widespread use in the treatment of a variety of neovascular and inflammatory intraocular conditions, including proliferative diabetic retinopathy, chronic cystoid macular edema, and chronic uveitis. Intraocular pressure (IOP) greater than 21 mm Hg occurs in approximately 42% of eyes following IVTA. Most of these patients are successfully treated with medical therapy, while a small percentage (1%) require glaucoma surgery for pressure management.1 We report a series of 3 patients who developed refractory glaucoma secondary to IVTA. All 3 were successfully treated with viscocanalostomy.

Patient 1 was a 54-year-old man with a previous central retinal vein occlusion. Patient 2 was a 51-year-old woman with a history of a superotemporal branch retinal vein occlusion. Both had undergone IVTA for treatment of macular edema associated with the vein occlusions. Patient 3 was a 77-year-old woman who had received IVTA for exudative age-related macular degeneration. All 3 patients developed raised IOPs following a single IVTA (20 mg/0.1 mL) that were not controlled despite maximal medical therapy. Preoperative IOPs were 38 mm Hg, 40 mm Hg, and 40 mm Hg and preoperative visual acuities were 20/200, 20/125, and 20/40 for patients 1, 2, and 3, respectively.

All patients underwent viscocanalostomy by P.K.W. after informed consent was obtained. Details of the procedure in all cases are as follows. A corneal traction suture was inserted and a fornix-based conjunctival flap was constructed superiorly. A superficial scleral flap measuring 5 mm × 5 mm × 250 μm was created with the base at the limbus (Figure 1). The corner of the scleral flap was elevated and dissected forward with a crescent blade kept parallel to the scleral surface advancing 2 mm into the clear cornea (Figure 2).

Place holder to copy figure label and caption
Figure 1.

Angle structures including Schlemm's canal (arrowhead). The white dotted line shows the superficial scleral flap.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Superficial scleral flap (5 mm × 5 mm × 250 μm) extending 2 mm into the clear cornea (arrowhead).

Graphic Jump Location

A deep scleral flap was constructed just within the first flap, deep enough to reveal only a thin translucent layer of sclera overlying the choroid. The deep flap was dissected forward in the same plane to reach the scleral spur, which was incised to reveal Schlemm's canal. The lateral edges of the deep flap were then extended 1 mm into the clear cornea. As the deep flap was dissected forward, the posterior then anterior trabecular meshwork were exposed before the flap was extended into the clear cornea, stripping off 1 to 2 mm of the Descemet membrane, creating a trabeculo-descemetic window. The endothelial lining of Schlemm's canal and the underlying juxtacanicular tissue were removed with a cellulose sponge until aqueous was seen seeping from the anterior chamber. The deep flap was excised with the roof of Schlemm's canal (Figure 3).

Place holder to copy figure label and caption
Figure 3.

Excised deep scleral flap, including the roof of Schlemm's canal (arrowhead), leaving the trabeculo-descemetic window (asterisk).

Graphic Jump Location

An ophthalmic viscoelastic device (Viscoat, Alcon Laboratories Inc, Fort Worth, Texas) was injected into the deep scleral lake and toward the cut ends of Schlemm's canal. Four 10.0 Vicryl sutures (Ethicon Inc, Somerville, New Jersey) closed the superficial scleral flap; the conjunctiva was also closed with 10.0 Vicryl sutures (Figure 4). Prednisolone, 1%, drops were used 4 times a day for 4 weeks followed by ketorolac, 0.5%, drops 4 times a day for 4 weeks. No perioperative or postoperative complications occurred, except for a small perforation of the trabeculo-descemetic window in patient 2. No antimetabolites, suture lysis, or postoperative needling were necessary.

Place holder to copy figure label and caption
Figure 4.

An ophthalmic viscoelastic device is used to form the intrascleral lake (arrow). The superficial flap is replaced and sutured.

Graphic Jump Location

Patients 1 and 3 had 6 months of follow-up and patient 2 completed 1 year. At 1 month, IOPs were 14 mm Hg in patient 1, 26 mm Hg in patient 2, and 10 mm Hg in patient 3. At 6 months postoperatively, IOPs were 10 mm Hg in patient 1, 16 mm Hg in patient 2, and 10 mm Hg in patient 3. Patient 2 had an IOP of 14 mm Hg at 1 year of follow-up. No antiglaucoma medication was necessary at any time postoperatively. Visual acuities at 6 months were 20/125, counting fingers, and 20/40 in patients 1, 2, and 3, respectively.

A few options have been suggested for the successful management of persistently elevated IOP following IVTA. These include trabeculectomy,1 laser trabeculoplasty,2 and pars plana vitrectomy.3

Viscocanalostomy has been shown to be effective in treating open-angle glaucoma with a reduced risk of the potentially sight-threatening complications, such as hypotony and endophthalmitis, compared with trabeculectomy.4 We report a series of 3 patients who were treated successfully with viscocanalostomy for refractory glaucoma secondary to IVTA.

Steroids induce glaucoma by lowering outflow facility through an unknown mechanism. Theories include the deposition of extracellular matrix in the trabecular meshwork.5 The complete success of viscocanalostomy in lowering IOP to acceptable levels without using antiglaucoma medication suggests that stripping the juxtacanalicular tissue and the inner waterproof endothelial lining of Schlemm's canal relieves the steroid-induced resistance to aqueous outflow. We feel this case series illustrates that the obstruction to aqueous outflow in IVTA-induced secondary glaucoma may lie predominantly in the juxtacanalicular tissue and the endothelium of Schlemm's canal. These structures are removed in viscocanalostomy as opposed to the corneoscleral or uveal trabecular meshwork, which are retained. This technique therefore sheds light on the possible biological mechanisms involved in the development of steroid-induced glaucoma and offers a safe and effective treatment option for such patients.

Correspondence: Dr Krishnan, St Paul's Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, England (radhikrishnan2004@yahoo.co.uk).

Author Contributions: Dr Krishnan, had full access to all the data in the study and takes responsibility for the integrity of this data.

Financial Disclosure: None reported.

Additional Contributions: Carl Groenwald, FRCOphth, provided the diagrams illustrating the technique of viscocanalostomy.

Jonas  JBDegenring  RFKreissig  IAkkoyun  IKamppeter  BA Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112 (4) 593- 598
PubMed
Viola  FMorescalchi  FStaurenghi  G Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol 2006;124 (1) 133- 134
PubMed
Agrawal  SAgrawal  JAgrawal  TP Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138 (4) 679- 680
PubMed
Wishart  PKWishart  MSPorooshani  H Viscocanalostomy and deep sclerectomy for the surgical treatment of glaucoma: a long term follow-up. Acta Ophthalmol Scand 2003;81 (4) 343- 348
PubMed
Kubota  TOkabe  HHisatomi  TYamakiri  KSakamoto  TTawara  A Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006;15 (2) 117- 119
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Angle structures including Schlemm's canal (arrowhead). The white dotted line shows the superficial scleral flap.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Superficial scleral flap (5 mm × 5 mm × 250 μm) extending 2 mm into the clear cornea (arrowhead).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Excised deep scleral flap, including the roof of Schlemm's canal (arrowhead), leaving the trabeculo-descemetic window (asterisk).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

An ophthalmic viscoelastic device is used to form the intrascleral lake (arrow). The superficial flap is replaced and sutured.

Graphic Jump Location

Tables

References

Jonas  JBDegenring  RFKreissig  IAkkoyun  IKamppeter  BA Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112 (4) 593- 598
PubMed
Viola  FMorescalchi  FStaurenghi  G Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol 2006;124 (1) 133- 134
PubMed
Agrawal  SAgrawal  JAgrawal  TP Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138 (4) 679- 680
PubMed
Wishart  PKWishart  MSPorooshani  H Viscocanalostomy and deep sclerectomy for the surgical treatment of glaucoma: a long term follow-up. Acta Ophthalmol Scand 2003;81 (4) 343- 348
PubMed
Kubota  TOkabe  HHisatomi  TYamakiri  KSakamoto  TTawara  A Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006;15 (2) 117- 119
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles